Unknown

Dataset Information

0

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.


ABSTRACT: PURPOSE:c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We investigated the feasibility of 89Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts. METHODS:In vitro membrane c-MET levels were determined by flow cytometry. HCC827ErlRes, an erlotinib-resistant clone with c-MET upregulation, was generated from the exon-19 EGFR-mutant human NSCLC cell line HCC827. Mice bearing HCC827 and HCC827ErlRes tumours in opposite flanks underwent 89Zr-onartuzumab PET scans. The HCC827-xenografted mice underwent 89Zr-onartuzumab PET scans before treatment and while receiving biweekly intraperitoneal injections of 100 mg/kg NVP-AUY-922 or vehicle. Ex vivo, tumour c-MET immunohistochemistry was correlated with the imaging results. RESULTS:In vitro, membrane c-MET was upregulated in HCC827ErlRes tumours by 213?±?44% in relation to the level in HCC827 tumours, while c-MET was downregulated by 69?±?9% in HCC827 tumours following treatment with NVP-AUY-922. In vivo, 89Zr-onartuzumab uptake was 26% higher (P?

SUBMITTER: Pool M 

PROVIDER: S-EPMC5486818 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

<sup>89</sup>Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Pool Martin M   Terwisscha van Scheltinga Anton G T AGT   Kol Arjan A   Giesen Danique D   de Vries Elisabeth G E EGE   Lub-de Hooge Marjolijn N MN  

European journal of nuclear medicine and molecular imaging 20170319 8


<h4>Purpose</h4>c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We investigated the feasibility of <sup>89</sup>Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth  ...[more]

Similar Datasets

| S-EPMC4745807 | biostudies-other
| S-EPMC4116087 | biostudies-literature
| S-EPMC8512011 | biostudies-literature
| S-EPMC4737475 | biostudies-literature
| S-EPMC6167529 | biostudies-literature
| S-EPMC6203283 | biostudies-literature
| S-EPMC5908310 | biostudies-literature
| S-EPMC5642894 | biostudies-literature
| S-EPMC6946129 | biostudies-literature
| S-EPMC7271293 | biostudies-literature